- Details
- Alicia Morgans and Neal Shore discuss the integration of the newly-approved Lutetium-617 into clinical practice for the treatment of advanced prostate cancer. The conversation revolves around the revolutionary potential of theranostics, where radiopharmaceuticals are linked with antibodies, such as PSMA. They further analyze the VISION trial, which demonstrated survival and quality of life benefit...
|
- Details
- Arnulf Stenzl joins Alicia Morgans to discuss the importance of proper and precise Transurethral Resection of Bladder Tumors (TURBT) as the first diagnostic step in bladder cancer treatment. He highlights the need for additional visualization techniques, such as photodynamic diagnosis or narrow-band imaging, to diagnose carcinoma in situ accurately. He also emphasizes the need to avoid piecemealin...
|
- Details
- Alicia Morgans is joined by Sam Chang in a conversation on supporting women in urology and the allyship of the AUA and The Society of Women in Urology. They discuss the Society of Women in Urology's efforts to support women and elevate this topic. Biographies: Sam S. Chang, M.D., M.B.A. Patricia and Rodes Hart Endowed Chair of Urologic Surgery Professor Department of Urology at Vanderbilt Universi...
|
- Details
- David Morris joins Ashley Ross in a conversation on genomics in prostate cancer specifically, in the unfavorable intermediate-risk patient. Drs Morris and Ross highlight the use of genomics in decision-making when considering what the best treatment option is for this group of individuals. They are particularly interested in determining if any of these intermediate-risk patients might actually be...
|
- Details
- Christopher Barbieri joins Matthew Cooperberg for a discussion about the molecular biology of localized prostate cancer. Dr. Barbieri explains how the underlying molecular and genomic features that separate prostate cancer subtypes can be studied using DNA sequencing and RNA sequencing. The conversation covers predictive markers including DECIPHER, PAM50, genomic mutations, and oncogenic drivers....
|
- Details
- Alicia Morgans and Patrick Hensley dive into the complexities surrounding the timing of cystectomy in BCG-unresponsive bladder cancer patients. Dr. Hensley emphasizes the need for a risk-stratified approach, particularly in identifying patients on the BCG failure spectrum, as these patients often present with worse outcomes. Dr. Hensley explains that high-risk patients should receive standard-of-c...
|
- Details
- Anne Schuckman and Alicia Morgans discuss the unique challenges and opportunities for women in urologic oncology. The two explore their own journeys in the field and provide suggestions on how young women seeking a career in urologic oncology can build their careers with confidence. Biographies: Anne K. Schuckman, MD, Director, LAC+USC Urologic Oncology, Keck Hospital of USC, USC Norris Cancer Hos...
|
- Details
- Stephen Williams sits down with Alicia Morgans to share some of the bladder cancer highlights from AUA 2022. Dr. Williams touches on a variety of topics in both muscle-invasive bladder cancer and non-muscle-invasive bladder cancer, including data from the QUILT study at UCLA, a pilot study on a comprehensive geriatric assessment tool at the University of Washington, the importance of psychological...
|
- Details
- Surena Matin, Jonathan Coleman, and Jean Hoffman-Censits join Sam Chang in a case-based discussion on approaches to the treatment of upper tract disease. The group evaluate a 75 years old, former smoker, who develops painless gross hematuria. His CT shows a 3-centimeter, left upper pole filling defect with a soft tissue mass. Labs are essentially normal. GFR is 65. The patient has good performance...
|
- Details
- Katie Murray joins Alicia Morgans to discuss reverse thermal mitomycin (JEMLYTO®) for primary chemoablation of upper tract urothelial carcinoma (UTUC) via a percutaneous nephrostomy tube. Based on results from the pivotal OLYMPUS trial, JELMYTO® is currently approved for low-grade UTUC. Dr. Murray speaks to two different methods of administration of the mitomycin gel that was allowed in this trial...
|
